High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma

Cancer Science

Volumn 99, Issue 9, 2008, Pages 1806-1812

  Sasahira, Tomonori ^a   Kirita, Tadaaki ^a   Oue, Naohide ^b   Bhawal, Ujjal Kumar ^a   Yamamoto, Kazuhiko ^a   Fujii, Kiyomu ^a   Ohmori, Hitoshi ^a   Luo, Yi ^a   Yasui, Wataru ^b   Bosserhoff, Anja Katrin ^c   Kuniyasu, Hiroki ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; COMPLEMENTARY RNA; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELANOMA INHIBITORY ACTIVITY PROTEIN; SECRETORY PROTEIN; SMALL INTERFERING RNA; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR RELA; VASCULOTROPIN C; VASCULOTROPIN D;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGB PROTEINS; HMGB1 PROTEIN; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM PROTEINS; NF-KAPPA B; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 50149119471     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00894.x     Document Type: Article

References (47)

1. Paterson IC, Eveson JW, Prime SS. Molecular changes in oral cancer may reflect aetiology and ethnic origin. Eur J Cancer B Oral Oncol 1996; 32B: 150-3.
2. Chen YJ, Lin SC, Kao T et al. Genome-wide profiling of oral squamous cell carcinoma. J Pathol 2004; 204: 326-32.
3. Hunter KD, Parkinson EK, Harrison PR. Profiling early head and neck cancer. Nat Rev Cancer 2005; 5: 127-35.
4. Woolgar JA, Rogers S, West CR, Errington RD, Brown JS, Vaughan ED. Survival and patterns of recurrence in 200 oral cancer patients treated by radical surgery and neck dissection. Oral Oncol 1999; 35: 257-65.
5. Lippman SM, Hong WK. Molecular markers of the risk of oral cancer. N Engl J Med 2001; 344: 1323-6.
6. Hershkovich O, Oliva J, Nagler RM. Lethal synergistic effect of cigarette smoke and saliva in an in vitro model: Does saliva have a role in the development of oral cancer? Eur J Cancer 2004; 40: 1760-7.
7. Blesch A, Bosserhoff AK, Apfel R et al. Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res 1994; 54: 5695-701.
8. Bosserhoff AK, Hein R, Bogdahn U, Buettner R. Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA. J Biol Chem 1996; 271: 490-5.
9. Koehler MR, Bosserhoff A, von Beust G et al. Assignment of the human melanoma inhibitory activity gene (MIA) to 19q13.32-q13.33 by fluorescence in situ hybridization (FISH). Genomics 1996; 35: 265-7.
10. Bosserhoff AK, Moser M, Hein R, Landthaler M, Buettner R. In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers. J Pathol 1999; 187: 446-54.
11. Poser I, Tatzel J, Kuphal S, Bosserhoff AK. Functional role of MIA in melanocytes and early development of melanoma. Oncogene 2004; 23: 6115-24.
12. Bosserhoff AK, Kaufmann M, Kaluza B et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997; 57: 3149-53.
13. Bosserhoff AK, Kondo S, Moser M et al. Mouse CD-RAP/MIA gene: Structure, chromosomal localization, and expression in cartilage and chondrosarcoma. Dev Dyn 1997; 208: 516-25.
14. Hau P, Ruemmele P, Kunz-Schughart LA et al. Expression levels of melanoma inhibitory activity correlate with time to progression in patients with high-grade glioma. Oncol Rep 2004; 12: 1355-64.
15. El Fitori J, Kleeff J, Giese NA et al. Melanoma inhibitory activity (MIA) increases the invasiveness of pancreatic cancer cells. Cancer Cell Int 2005; 5: 3.
16. Lee KL, Pentecost BT, D'Anna JA, Tobey RA, Gurley LR, Dixon GH. Characterization of cDNA sequences corresponding to three distinct HMG-1 mRNA species in line CHO Chinese hamster cells and cell cycle expression of the HMG-1 gene. Nucleic Acids Res 1987; 15: 5051-68.
17. Rauvala H, Pihlaskari R. Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J Biol Chem 1987; 262: 16625-35.
18. Sasahira T, Kirita T, Bhawal UK et al. Expression of receptor for advanced glycation end products (RAGE) is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch 2007; 450: 287-95.
19. Sasahira T, Kirita T, Bhawal UK, Yamamoto K, Kuniyasu H. Significance of expression of receptor for advanced glycation end products (RAGE) in recurrence of human oral squamous cell carcinoma. Histopathol 2007; 51: 166-72.
20. Bhawal UK, Ozaki Y, Nishimura M et al. Association of expression of receptors for advanced glycation end-products (RAGE) and invasive and metastatic activity of oral squamous cell carcinoma. Oncology 2005; 69: 246-55.
21. Kuniyasu H, Chihara Y, Kondo H. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer 2003; 104: 722-7.
22. Kuniyasu H, Chihara Y, Kondo H, Ohmori H, Ukai R. Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep 2003; 10: 1863-8.
23. Kuniyasu H, Chihara Y, Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 2003; 10: 445-8.
24. Kuniyasu H, Oue N, Wakikawa A et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002; 196: 163-70.
25. Kuniyasu H, Sasaki T, Sasahira T, Ohmori H, Takahashi T. Depletion of tumor-infiltrating macrophages is associated with amphoterin expression in colon cancer. Pathobiology 2004; 71: 129-36.
26. Kuniyasu H, Yano S, Sasaki T, Sasahira T, Sone S, Ohmori H. Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am J Pathol 2005; 166: 751-60.
27. Stros M, Ozaki T, Bacikova A, Kageyama H, Nakagawara A. HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J Biol Chem 2002; 277: 7157-64.
28. Poser I, Golob M, Buettner R, Bosserhoff AK. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 2003; 23: 2991-8.
29. Golob M, Buettner R, Bosserhoff AK. Characterization of a transcription factor binding site, specifically activating MIA transcription in melanoma. J Invest Dermatol 2000; 115: 42-7.
30. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-68.
31. Ikuta M, Podyma KA, Maruyama K, Enomoto S, Yanagishita M. Expression of heparanase in oral cancer cell lines and oral cancer tissues. Oral Oncol 2001; 37: 177-84.
32. Parkkinen J, Raulo E, Merenmies J et al. Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. J Biol Chem 1993; 268: 19726-38.
33. Czura CJ, Wang H, Tracey KJ. Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res 2001; 7: 315-21.
34. Taguchi A, Blood DC, del Toro G et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354-60.
35. Sasahira T, Akama Y, Fujii K, Kuniyasu H. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch 2005; 446: 411-5.
36. Sasahira T, Sasaki T, Kuniyasu H, Akama Y, Fujii K. Interleukin-15 and transforming growth factor alpha are associated with depletion of tumor-associated macrophages in colon cancer. J Exp Clin Cancer Res 2005; 24: 69-74.
37. Bosserhoff AK, Stoll R, Sleeman JP, Bataille F, Buettner R, Holak TA. Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity. Lab Invest 2003; 83: 1583-94.
38. Jachimczak P, Apfel R, Bosserhoff AK et al. Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques. Int J Cancer 2005; 113: 88-92.
39. Bauer R, Humphries M, Faessler R, Winklmeier A, Craig SE, Bosserhoff AK. Regulation of integrin activity by MIA. J Biol Chem 2006; 281: 11669-77.
40. Dietrich T, Onderka J, Bock F et al. Inhibition of inflammatory lymphangiogenesis by integrin alpha5 blockade. Am J Pathol 2007; 171: 361-72.
41. Kobayashi S, Kishimoto T, Kamata S, Otsuka M, Miyazaki M, Ishikura H. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 2007; 98: 726-33.
42. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002; 2: 573-83.
43. O-charoenrat P, Rhys-Evans P, Eccles SA. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer 2001; 92: 556-68.
44. Stacker SA, Caesar C, Baldwin ME et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7: 186-91.
45. Momose F, Araida T, Negishi A, Ichijo H, Shioda S, Sasaki S. Variant sublines with different metastatic potentials selected in nude mice from human oral squamous cell carcinomas. J Oral Pathol Med 1989; 18: 391-5.
46. Khan MH, Yasuda M, Higashino F, Haque S, Kohgo T, Nakamura M, Shindoh M. nm23-H1 suppresses invasion of oral squamous cell carcinoma-derived cell lines without modifying matrix metalloproteinase-2 and matrix metalloproteinase-9 expression. Am J Pathol 2001; 158: 1785-91.
47. Fleming ID, Cooper JS, Henson DE et al. AJCC Cancer Staging Manual. Lippincott-Raven, Philadelphia, 1997.